Cargando…
New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy
Development of selective inhibitors of BRAF has improved the survival of patients with BRAF-mutant melanoma. The progression-free survival after treatment with a BRAF inhibitor is modest, however, and BRAF inhibitors induce cutaneous toxicity, likely due to paradoxical activation of the mitogen-acti...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075957/ https://www.ncbi.nlm.nih.gov/pubmed/25018652 http://dx.doi.org/10.2147/DHPS.S39568 |